Letrozole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Locally Advanced Breast Cancer
Conditions
Locally Advanced Breast Cancer
Trial Timeline
Mar 1, 2003 → Jan 21, 2009
NCT ID
NCT00237133About Letrozole
Letrozole is a approved stage product being developed by Novartis for Locally Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00237133. Target conditions include Locally Advanced Breast Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Locally Advanced Breast Cancer were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01908556 | Approved | UNKNOWN |
| NCT00856050 | Phase 2 | Completed |
| NCT00688909 | Approved | Completed |
| NCT00549822 | Phase 2 | Terminated |
| NCT00414076 | Phase 2 | Terminated |
| NCT00382070 | Phase 3 | Active |
| NCT00332852 | Phase 3 | Completed |
| NCT00330317 | Phase 3 | Completed |
| NCT00329940 | Phase 3 | Completed |
| NCT00171808 | Phase 2 | Completed |
| NCT00237133 | Approved | Completed |
| NCT00237224 | Approved | Completed |
| NCT00291135 | Phase 2 | Completed |
| NCT00240942 | Phase 2 | Completed |
| NCT00333047 | Phase 2/3 | Completed |
| NCT00241046 | Approved | Terminated |
| NCT00014638 | Approved | Completed |
| NCT00535418 | Phase 2/3 | Completed |
| NCT00333086 | Phase 2 | Completed |
Competing Products
20 competing products in Locally Advanced Breast Cancer